Winthrop and colleagues have reviewd the occurrence of opportunistic infections (OIs) associated with the use of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), showing that Herpez zoster (HZ) was the most common OI reported with JAK inhibitors in clinical trials, although tuberculosis (TB) and other OIs were also reported.
Dr. John Cush RheumNow
3 years 10 months ago
National Swedish Hip & Knee OA registry compared outcomes if pts seen in-person (F2F) or digitally (online) in 6946 pts - both groups improved at 3 mos; but digital pts had larger improvement at 3 mos (pain & Function) -- unknown if clinically meaningful https://t.co/yD4zAVpuhh https://t.co/IjqnTjXpbC
A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).
Dr. John Cush RheumNow
3 years 10 months ago
Undiagnosed RA During the Pandemic
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
https://t.co/qEcEF8ukxm https://t.co/PcXAxrjT24
Dr. John Cush RheumNow
3 years 10 months ago
Full read review of advances in bone biology leading to drug development (denosumab, romosuzumab, Burosumab), advances in Pagets and rickets and key regulatory molecules for bone remodeling, RANK, RANKL, OPG, & sclerostin https://t.co/CMMzIrZRUa https://t.co/ABhaHxP8y2
Dr. John Cush RheumNow
3 years 10 months ago
Dr. Patricia Harkins, @DrTrishHarkins, is new to the #ACR22 RheumNow reporter team.
From Dr. Harkins, "I am really looking forward to the new "Ignite sessions", as well as working with the Rheum Now Faculty for the first time!"
Follow her for real-time #ACR22 coverage! https://t.co/dpDfNJs1V4
Dr. John Cush RheumNow
3 years 10 months ago
"I can't wait to see how the new format works: the poster hall, the SPARK talks, and to see a whole lot of people in person!"
Follow Dr. David Liew, @drdavidliew, for real-time #ACR22 coverage! https://t.co/RBbLyqrBNT
Dr. John Cush RheumNow
3 years 10 months ago
Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, gold, MTX, 6-MP, NSAIDs, ASA, SSZ, Minocin... https://t.co/tAaW41h7xS https://t.co/fn8sNbeslH
Dr. John Cush RheumNow
3 years 10 months ago
From the Crypt: Rheumatology Dead Word Cemetery
Arthritis, Rheumatic Disease and Rheumatology cover a catalogue of ageless disorders w/decades, if not centuries, of history behind them.Enjoy our blog on retired Rheum sayings, as so decreed by RheumNow.
https://t.co/WyBFEVa1h5 https://t.co/eE3HQ4N5Ia
Dr. John Cush RheumNow
3 years 10 months ago
2022 New Drug Approvals
Download today!
https://t.co/nz91Ckw0AZ https://t.co/QieTvcqjcy
Dr. John Cush RheumNow
3 years 10 months ago
“I am looking forward to the ACR to hear about the ground-breaking results from basic science to the new treatments. I am delighted to be part of the RheumNow faculty covering the many topics from #ACR22. “
Follow Dr. Chan at @synovialjoints for real-time coverage of #ACR22. https://t.co/i6OZRHlBaE
Dr. John Cush RheumNow
3 years 10 months ago
New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
This and more on the latest RheumNow podcast.
https://t.co/4YBqHjI3VL https://t.co/g2pE72pyEk
Dr. John Cush RheumNow
3 years 10 months ago
“At the ACR I am looking forward to meeting colleagues in person, having some great food in Philadelphia and to learning alot as a RheumNow reporter!”
Dr. Janet Pope is back for #ACR22 as a RheumNow reporter, sharing real-time coverage on many topics. Follow her @Janetbirdope https://t.co/ROD7oan4KZ
Dr. John Cush RheumNow
3 years 10 months ago
SLE T2T - Lupus Low Disease Activity State Predicts Outcomes
A prospective study shows that T2T with a goal of LLDAS and remission has been shown to improve mortality risk.
https://t.co/WRaqjdVi9G https://t.co/3guKt0Qby9
